Bimekizumab maintenance of response and safety in patients with moderate to severe plaque psoriasis: Results from the open‑label extension period (Weeks 48–144) of the BE RADIANT phase 3b trial

Sustained efficacy and safety of bimekizumab in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: Results from the Phase 3 BE COMPLETE study and its open-label extension up to 1 year